A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
The primary objective of the study was to demonstrate superior efficacy of Xevinapant (Debio 1143) vs placebo when added to chemoradiotherapy (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).
Inclusion Criteria:
Exclusion Criteria:
Birmingham, Alabama 35233, United States
Washington D.C., District of Columbia 20007, United States
Fort Wayne, Indiana 46804, United States
Louisville, Kentucky 40241, United States
New York, New York 10016, United States
Oklahoma City, Oklahoma 73104, United States
Charleston, South Carolina 29425, United States
Graz, Austria
Santo André, Brazil
Ostrava-Poruba, Czechia
Mannheim, Germany
Petach Tiqva, Israel
Chuo-ku Tokyo, Japan
Nagaizumi-cho, Japan
Kazan', Russia
Krasnoyarsk, Russia
Saint Petersburg, Russia
Yaroslavl, Russia
A Coruña, Galicia, Spain